TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04722328

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF metagenomic next generation sequencing (mNGS)
Description: TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF metagenomic next generation sequencing (mNGS)
Description: TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
Study: NCT06342024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio group
Description: Participants will be giving 1.5 ounces of pistachios to consume during the 6-month trial.
Study: NCT04882319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-5000 Topical Patch
Description: HP-5000, placebo and saline will be administered simultaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-5000 Placebo Patch
Description: HP-5000, placebo and saline will be administered simultaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Patch
Description: HP-5000, placebo and saline will be administered simultaneously
Study: NCT06004778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Support Program
Description: In studies conducted on adolescents with poor sleep quality, no study using motivational interviewing technique was found.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational support
Description: educational support
Study: NCT04815382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Upper Limb Orthosis
Description: The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months
Study: NCT05134194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine
Description: Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/eribulin/gemcitabine/vinorelbine
Description: Capecitabine or eribulin or gemcitabine or vinorelbine
Study: NCT05122221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide
Description: Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRTE7A2-01 TCR-T Cell
Description: On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
Study: NCT04652544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
Study: NCT05840094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is injected intravenously with a dose of 0.1mCi/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is injected intravenously with a dose of 0.1mCi/kg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR STIR
Description: The overall scanning time of MR is about 13min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR STIR
Description: The overall scanning time of MR is about 13min.
Study: NCT05656716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
Study: NCT06502444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Forward Together Activity Intervention
Description: The activity intervention program consists of videos and handouts to encourage participants to access these materials if they wish to increase their physical activity. The program lasts 8 weeks. Participants may access program materials for an additional four weeks after the program ends
Study: NCT04993820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control
Description: Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
Study: NCT05840094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
Study: NCT05134675

Intervention type: DIETARY_SUPPLEMENT
Intervention: Homemade beer
Description: The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Homemade beer
Description: The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
Study: NCT04710524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 150 mg BID
Description: FM101 (150 mg) BID for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 300 mg BID
Description: FM101 (300 mg) BID for 13 weeks
Study: NCT05840094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
Study: NCT05593926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myota Metabolic Regulator
Description: The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
Study: NCT05263128

Intervention type: OTHER
Intervention: Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome
Description: To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey

Intervention type: OTHER
Intervention: Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome
Description: To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
Study: NCT05585086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint Oil Inhalation
Description: Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
Study: NCT04838886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based Pilates Exercise
Description: The group that will receive telerehabilitation-based pilates training via telerehabilitation
Study: NCT05261568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROGRESSIVE RELAXATION EXERCISE
Description: Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
Study: NCT05648708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combine Adductor Canal & Sciatic Nerve Block
Description: The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combine Femoral & Sciatic Nerve Block
Description: The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study: NCT06315049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy sessions to reduce anxiety
Study: NCT05835219

Intervention type: DRUG
Intervention: REBYOTA™
Description: REBYOTA™ is administered in the rectum
Study: NCT05297448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD
Description: Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Twice Daily
Study: NCT05400707

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of vital signs
Description: heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of patient mobility at presentation
Description: Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of level of consciousness by AVPUC scale
Description: Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of symptoms patients presenting when admitted to ED
Description: Questionnaire with a predefined list of 37 symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of what matters most in patients of 65 years and older
Description: Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Decision-making in senior physicians
Description: Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Numeric Rating Scale (NRS)
Description: The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale (CFS)
Description: The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
Study: NCT06374199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Med-South Lifestyle Intervention for Pregnancy--Arm 1
Description: Intervention includes lifestyle counseling and food provisions including extra virgin olive oil and nuts
Study: NCT06142149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonographic evaluation
Description: Screen the front of neck using ultrasound
Study: NCT05950256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N95 mask and surgical mask
Description: Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 mask and surgical mask
Description: Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
Study: NCT06374199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Med-South Lifestyle Intervention for Pregnancy--Arm 2
Description: Intervention includes lifestyle counseling and food provisions including extra virgin olive oil, nuts, and medically tailored meals
Study: NCT06338163

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Polihexanide-based bundle
Description: Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard bundle
Description: Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
Study: NCT04543955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat (Low-Dose)
Description: Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat (High-Dose)
Description: Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
Study: NCT04478149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafelyYou
Description: technology to detect and prevent falls

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: technology present but not activated
Study: NCT05768841

Intervention type: BEHAVIORAL
Intervention: mental health issues
Description: survey on mental health issues in endurance athletes
Study: NCT05454202

Intervention type: DEVICE
Intervention: ANI
Description: Pain measurement during care procedures in palliative care
Study: NCT05502471

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Zonulin
Description: Serum zonulin level

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Zonulin
Description: Serum zonulin level

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Occludin
Description: Serum occludin level

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Occludin
Description: Serum occludin level
Study: NCT04704895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Total parenteral nutrition
Description: Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
Study: NCT04689594

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CLS2702C/CLS2702D
Description: CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device
Study: NCT06490120

Intervention type: OTHER
Intervention: sampling method
Description: feasibility outcomes will be compared between the 3 groups

Intervention type: OTHER
Intervention: sampling method
Description: feasibility outcomes will be compared between the 3 groups

Intervention type: OTHER
Intervention: sampling method
Description: feasibility outcomes will be compared between the 3 groups
Study: NCT05940727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual macroalgae consumption
Description: The participant have a habitual macroalgae consumption at baseline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual macroalgae consumption
Description: The participant have a habitual macroalgae consumption at baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No macroalgae consumption
Description: The participants exclude any macroalgae products from their diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No macroalgae consumption
Description: The participants exclude any macroalgae products from their diet
Study: NCT06012721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: Food effect healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: Food effect healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: Food effect healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: Food effect healthy subjects
Study: NCT05618236

Intervention type: DRUG
Intervention: Group N; neostigmine+atropine
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.

Intervention type: DRUG
Intervention: GROUP S; decurarized with sugammadex.
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
Study: NCT05996588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1 % Injectable Suspension
Description: Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously